Biotech Values

[TwoNE1]

LPTX - Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress

Mon, September 13, 2021, 12:00 PM

- DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer

- In patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in patients with DKK1-high tumors

- Further results will be presented at the ESMO 2021 Congress from September 16 to 21, 2021

- Company to host conference call on Friday, September 17, 2021 at 8:00 a.m. ET

https://finance.yahoo.com/news/leap-therapeutics-present-data-distinguish-100000549.html

FYI: Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01
Jan 03, 2020, 08:53 ET

[...]

Under the terms of the agreement, Leap will receive an upfront cash payment of $3 million from BeiGene in exchange for granting BeiGene an option to an exclusive license to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand, and will be eligible to receive an additional payment from BeiGene upon BeiGene's exercise of the option following initial proof-of-concept studies. Additionally, Leap is eligible to receive payments from BeiGene based upon the achievement of certain development, regulatory, and sales milestones for a total deal value of up to $132 million, together with tiered royalties on any product sales of DKN-01 in the licensed territory. BeiGene will also make a $5 million equity investment in Leap as part of the contemporaneous $27 million equity financing.

[...]

https://www.prnewswire.com/news-releases/leap-therapeutics-and-beigene-announce-exclusive-option-and-license-agreement-for-dkn-01-and-leap-announces-27-million-equity-financing-300980854.html